HealthcareServices

Preclinical Assets Market Insights Report: Opportunities and Drivers 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the preclinical assets market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Preclinical Assets Market by the end of 2030?

The preclinical assets market has experienced robust growth in recent years. This market is projected to expand from $6.38 billion in 2025 to $7.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. Historically, this expansion has been driven by factors such as a surge in pharmaceutical R&D investments, the proliferation of early-stage drug discovery initiatives, an increasing dependence on animal testing, a heightened need for generating safety data, and the rising trend of outsourcing preclinical studies.

The preclinical assets market is anticipated to experience substantial growth in the upcoming years. Its value is projected to escalate to $10.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period stems from factors such as the increasing adoption of human-relevant preclinical models, a heightened demand for accelerated drug development timelines, the broadening of personalized medicine pipelines, the expanding integration of AI in preclinical research, and a greater regulatory focus on data robustness. Significant trends expected in this period include the increased utilization of advanced preclinical models, a rise in the adoption of patient-derived xenograft and organoid models, a growing need for integrated preclinical services, an expansion of safety and toxicology studies, and a stronger emphasis on translational research.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What Drivers Are Shaping Future Opportunities In The Preclinical Assets Market?

The increasing demand to reduce expenditures associated with clinical trials is anticipated to drive expansion in the preclinical asset market moving ahead. These costs encompass the outlays for designing, executing, and overseeing studies that evaluate the safety, effectiveness, and potential advantages of novel medical interventions, like drugs, medical devices, or treatment methods. Such trials yield crucial information regarding the safety, effectiveness, and possible adverse reactions of preclinical assets, thereby aiding in confirming their therapeutic promise in humans. For example, in February 2023, Genetic Engineering and Biotechnology News, a US-based platform that provides the latest information on genetic engineering and biotechnology, reported that the expense for developing a new drug among the top 20 global biopharma companies increased by 15%, from $298 million in 2022 to around $2.3 billion in 2023. This figure accounts for the expenditures involved in drug development through clinical trials. Consequently, the escalating imperative to control clinical trial expenditures is fueling the expansion of the preclinical asset market.

Which Segments Are Gaining Traction In The Preclinical Assets Market?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Which Competitive Trends Are Impacting The Structure Of The Preclinical Assets Market?

Leading companies in the preclinical assets market are increasingly focusing on establishing strategic alliances to accelerate the identification and development of innovative drug candidates. These partnerships allow for the sharing of specialized research expertise, provide access to novel targets, and facilitate the advancement of early-stage preclinical assets. For instance, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, an India-based research and drug development company, announced an expanded strategic collaboration to continue progress on several innovative preclinical and early-stage clinical assets. This partnership extends the existing collaboration between AbbVie and Scripps Research. Furthermore, Calibr will present AbbVie with a defined number of new discovery targets and preclinical assets of mutual interest for potential option considerations.

Who Are The Prominent Global Companies Shaping The Preclinical Assets Market Landscape?

Major companies operating in the preclinical assets market are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Preclinical Assets Market?

North America was the largest region in the preclinical assets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Preclinical Assets Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Browse Through More Reports Similar to the Global Preclinical Assets Market 2026, By The Business Research Company

Enterprise Asset Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/enterprise-asset-management-global-market-report

Asset Management Market 2026

https://www.thebusinessresearchcompany.com/report/asset-management-market

Digital Asset Custody Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-asset-custody-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795